Idenix Announces Exercise of Underwriters' Over-Allotment Option and Completion of Sale

CAMBRIDGE, Mass., Nov. 28  /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) announced today that on November 14, 2005 the underwriters of its public offering exercised in full their over-allotment option and completed the purchase at the public offering price of $20.61 per share of 1,130,387 additional shares of Idenix common stock from certain stockholders of the Company.  The Company did not receive any proceeds from the over-allotment option exercise or sale of the shares by selling stockholders.

Morgan Stanley & Co. Incorporated acted as the sole book runner for the offering.  Bear, Stearns & Co. Inc. acted as co-lead manager for the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities in any jurisdiction in which such offer, solicitation or sale is not permitted. A copy of the final prospectus, including a final prospectus supplement, may be obtained from the Prospectus Department of Morgan Stanley (180 Varick Street, 2nd Floor, New York, New York 10014, telephone [phone]).

About Idenix

Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus (HIV).  Idenix's headquarters are located in Cambridge, Massachusetts and it has drug discovery and development operations in Montpellier, France and drug discovery operations in Cagliari, Italy.

Idenix Pharmaceuticals' Contact

Teri Dahlman, 617-995-9905 

DATASOURCE: Idenix Pharmaceuticals, Inc.



CONTACT: Teri Dahlman of Idenix Pharmaceuticals, Inc., [phone]



Web site:  http://www.idenix.com/

Copyright